Targepeutics

Q: What is Targepeutics's official website?

Targepeutics's official website is www.targepeutics.com

Q: What is Targepeutics's Revenue?

Targepeutics's revenue is <$5 Million

Q: How many employees does Targepeutics have?

Targepeutics has 1-10 employees

Q: What industry does Targepeutics belong to?

Targepeutics is in the industry of: Business Services , Research & Development

Q: What is Targepeutics competition?

Targepeutics top competitors include: Moleculin , Ddnews , OncoSynergy , CellSight Technologies

Q: What technology does Targepeutics use?

Some of the popular technologies that Targepeutics uses are: WordPress.org, PHP, Cloudflare Website Optimization, Microsoft 365

Q: How do I contact Targepeutics?

Targepeutics contact info: Phone number: (717) 571-2402 Website: www.targepeutics.com

Q: What does Targepeutics do?

Targepeutics is focused on developing GB-13, a targeted immunotoxin for the treatment of aggressive brain cancers such as Glioblastoma and Diffuse Midline Glioma. The company aims to provide innovative and biologically targeted therapies that have been largely absent in recent years. With orphan drug designation from the FDA, Targepeutics is advanc... ing GB-13 to clinical trials, aiming to improve survival rates for patients facing these conditions. Their mission is to deliver effective treatment options to patients and their families, addressing a significant unmet need in brain cancer care. Read More

Q: Is Targepeutics a public company?

Targepeutics is private company therefore does not currently have an official ticker symbol

Business Services · Pennsylvania, United States · 1-10 Employees

View Company Info for Free

Overview

Headquarters

1214 W End Ave Ste 1011, Hummelstown, Pe...

Phone Number

(717) 571-2402

Website

www.targepeutics.com

Revenue

<$5 Million

Industry

Business Services

Research & Development

About Targepeutics

Targepeutics is focused on developing GB-13, a targeted immunotoxin for the treatment of aggressive brain cancers such as Glioblastoma and Diffuse Midline Glioma. The company aims to provide innovative and biologically targeted therapies that have been largely absent in recent years. With orphan drug designation from the FDA, Targepeutics is advancing GB-13 to clinical trials, aiming to improve survival rates for patients facing these conditions. Their mission is to deliver effective treatment options to patients and their families, addressing a significant unmet need in brain cancer care.Explore more

Is this data correct?

View contact profiles from Targepeutics

SIC Code 87,873NAICS Code 54,541Show more

Targepeutics Org Chart

Sil Lutkewitte

Chief Executive Officer

Phone

Randy Schrecengost

Chief Scientific Officer

Phone

Get the full picture

Compare Similar Companies to Targepeutics

Compare insights from companies similar to Targepeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.